The results of two phase III clinical studies on hypoglycemic and weight loss drugs jointly completed by several research and development units in China were published in the international academic journal “Nature” on the 18th, Beijing time. This is also the first time since the magazine was founded that the results of two phase III clinical studies were simultaneously published back-to-back in the field of metabolic and endocrine diseases. The results of the two phase III clinical studies published this time are studies on single drug treatment of mast peptides in type 2 diabetics and studies on combined use with oral hypoglycemic agents, both based on clinical data from Chinese patients.

The results of two phase III clinical studies on hypoglycemic and weight loss drugs jointly completed by several research and development units in China were published in the international academic journal “Nature” on the 18th, Beijing time. This is also the first time since the magazine was founded that the results of two phase III clinical studies were simultaneously published back-to-back in the field of metabolic and endocrine diseases. The results of the two phase III clinical studies published this time are studies on single drug treatment of mast peptides in type 2 diabetics and studies on combined use with oral hypoglycemic agents, both based on clinical data from Chinese patients.